Q-omics provides the consensus-scored MRPL15 profile across patient tissues and cancer cell-line models. MRPL15 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MRPL15 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, MRPL15 protein abundance shows 31,098 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where MRPL15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL15 survival associations across molecular data types. MRPL15 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL15 RNA expression–survival associations across cancer types. High MRPL15 expression shows unfavorable associations in UVM, HNSC, LUAD, STAD, UCEC and KICH. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MRPL15 RNA expression.
This table summarizes MRPL15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPL15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL15 shows lower tumor expression in THCA and higher tumor expression in HNSC, LUAD, STAD, BLCA and LUSC. The HNSC box plot shows higher MRPL15 RNA expression in tumor versus normal tissue (log2 FC = +0.785, t-test p < 0.001).
This table shows molecular features associated with MRPL15 in patient tissues and cancer cell lines. In patient samples, MRPL15 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
